EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Innovative Se‐Flutamide Derivatives: Enhanced Activity Toward Androgen Receptor (AR)‐Dependent and ‐Independent Prostate Cancer Cells

Cristina Morán-Serradilla, Carmen Sanmartín iD, Asif Raza, Ignacio Encío, Daniel Plano iD, Arun K Sharma

Archiv der Pharmazie · 2025

DOI: 10.1002/ardp.70119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Cristina Morán-Serradilla und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Navarra, Irunlarrea, Spain. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Receptors, Androgen, Antineoplastic Agents, Flutamide. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The research reported here was partially supported by National Institutes of Health instrumentation grants: 1S10OD028589-01 and 1S10RR023439-01 for the X-ray e…, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sixteen novel selenoderivatives of flutamide, which is used for treating androgen receptor (AR)‐dependent prostate cancer, were developed. All the Se derivatives displayed promising activity against the NCI‐60 human cancer cell line panel, which also includes two AR‐independent prostate cancer cell lines, DU‐145 and PC‐3. Conversely to flutamide, compounds a2 , a5 , and b4 exhibited a potent antiproliferative effect toward AR‐dependent LNCaP cells. Several cell death inhibitors were used to determine the underlying regulated cell death processes of a5 . Regarding its mechanism of action in these cells, this compound promoted apoptosis by activating both intrinsic and extrinsic apoptotic pathways, without generating reactive oxygen species (ROS). Besides, it induced the G0/G1 cell cycle arrest. Altogether, it could be concluded that this Se‐flutamide analog could be a feasible and promising candidate for further development for the treatment of both AR‐dependent and ‐independent prostate cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsReceptors, AndrogenAntineoplastic AgentsFlutamideOrganoselenium CompoundsHumansMaleCell ProliferationApoptosisCell Line, TumorStructure-Activity RelationshipDrug Screening Assays, AntitumorMolecular StructureDose-Response Relationship, DrugReactive Oxygen Species

Stichwörter der Autor:innen

flutamideprostate cancerselenium

Substanzen

Receptors, AndrogenAntineoplastic AgentsFlutamideAR protein, humanReactive Oxygen SpeciesOrganoselenium Compounds

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, University of Navarra, Irunlarrea, Spain.
  • Department of Molecular and Precision Medicine, Penn State Cancer Institute, Penn State College of Medicine, Hershey, USA.
  • Department of Health Sciences, Public University of Navarra, Pamplona, Spain.

ORCID-Profile: Carmen Sanmartín, Daniel Plano

Förderung

  • The research reported here was partially supported by National Institutes of Health instrumentation grants: 1S10OD028589-01 and 1S10RR023439-01 for the X-ray e…
  • National Institutes of Health

Zitieren

APA

Morán-Serradilla, C., Sanmartín, C., Raza, A., Encío, I., Plano, D., & Sharma, A. K. (2025). Innovative Se‐Flutamide Derivatives: Enhanced Activity Toward Androgen Receptor (AR)‐Dependent and ‐Independent Prostate Cancer Cells. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70119

Vancouver

Morán-Serradilla C, Sanmartín C, Raza A, Encío I, Plano D, Sharma AK. Innovative Se‐Flutamide Derivatives: Enhanced Activity Toward Androgen Receptor (AR)‐Dependent and ‐Independent Prostate Cancer Cells. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70119

BibTeX
@article{MornSerradilla2025,
  author = {Morán-Serradilla, Cristina and Sanmartín, Carmen and Raza, Asif and Encío, Ignacio and Plano, Daniel and Sharma, Arun K},
  title = {Innovative Se‐Flutamide Derivatives: Enhanced Activity Toward Androgen Receptor (AR)‐Dependent and ‐Independent Prostate Cancer Cells},
  journal = {Archiv der Pharmazie},
  year = {2025},
  doi = {10.1002/ardp.70119}
}
Kostenlos starten →